BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/12/2014 8:41:00 PM | Browse: 711 | Download: 557
Publication Name World Journal of Gastroenterology
Manuscript ID 3639
Country United States
Received
2013-05-11 10:26
Peer-Review Started
2013-05-11 13:46
To Make the First Decision
2013-06-09 10:06
Return for Revision
2013-06-20 11:07
Revised
2013-06-29 03:15
Second Decision
2013-08-06 08:49
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-08-06 17:35
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-08-29 12:18
Publish the Manuscript Online
2013-09-14 11:17
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Autobiography
Article Title Quality of compounded topical 2% diltiazem hydrochloride formulations for anal fissure
Manuscript Source Invited Manuscript
All Author List Monil Shah, Laura Sandler, Vishwas Rai, Charu Sharma and Lakshmi Raghavan
Funding Agency and Grant Number
Funding Agency Grant Number
Ventrus Biosciences, Inc., New York, NY, United States
Corresponding Author Monil Shah, PharmD, MBA, Ventrus Biosciences, Inc., 99 Hudson Street, 5th Floor, New York, NY 10013, United States. mshah@ventrusbio.com
Key Words Anal fissure; Pharmacy compounding; Topical diltiazem; Formulation potency; Content uniformity
Core Tip The use of topical 2% diltiazem hydrochloride for treating anal fissures is supported by multiple clinical trials and is recommended in published practice parameters. As no commercially manufactured formulation of topical 2% diltiazem has been approved yet by the Food and Drug Administration for the treatment of anal fissure, prescriptions for the medication need to be extemporaneously compounded by retail pharmacies. Employing high-performance liquid chromatography analysis of topical 2% diltiazem formulations compounded by a sampling of pharmacies, we found a notable trend toward lack of content uniformity and misbranding of potency, suggesting that many patients might not receive the anticipated relief of anal-fissure pain.
Publish Date 2013-09-14 11:17
Citation Shah M, Sandler L, Rai V, Sharma C, Raghavan L. Quality of compounded topical 2% diltiazem hydrochloride formulations for anal fissure. World J Gastroenterol 2013; 19(34): 5645-5650
URL http://www.wjgnet.com/1007-9327/full/v19/i34/5645.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i34.5645
Full Article (PDF) WJG-19-5645.pdf
Manuscript File 3639-Review.docx
Answering Reviewers 3639-Answering reviewers.pdf
Copyright License Agreement 3639-Copyright assignment.pdf
Peer-review Report 3639-Peer review(s).pdf
Scientific Editor Work List 3639-Scientific editor work list.doc